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Summary 
In normal mice neonatal injection  of staphylococcal enterotoxin B (SEB) induces tolerance in 
T cells that express reactive T cell receptor (TCK) V/~ regions. To determine if a T cell neonatal 
defect was present in MRL-Ipr/Ipr  mice, 20 #g of SEB was injected intraperitoneally  every other 
day into VBS.2 TCR transgenic and nontransgenic MR.b +/+ and MKL-Ipr/Ipr  mice from birth 
to 2 wk of age. At 2 wk of age, V~8 + T cells were depleted,  and SEB reactivity was lost, in 
spleen, lymph node, and thymus. These effects were equivalent in +/+ and Ipr/lpr  SEB-tolerized 
mice. However, MILL-Ipr/Ipr  mice failed to maintain neonatal tolerance. By 4 wk of age, there 
was a dramatic increase in T cells expressing V~8.2 in the peripheral lymph nodes of MRblpr/lt,r 
mice but not MRD +/+  mice. In vitro stimulation with SEB or TCR crosslinking  revealed 
a total loss of neonatal tolerance 2 wk after cessation of SEB treatment in Ipr/Ipr  mice, but not 
+/+  mice.  The time-course of recovery of V~8 + T  cells and reactivity to SEB  and TCR 
crosslinking in the thymus of MRL-Ipr/Ipr  mice was similar to that in the lymph node. Thymectomy 
at 2 wk of age eliminated tolerance loss in lymph nodes of MtLL-Ipr/Ipr  mice at 4 wk of age, 
indicating that loss of peripheral tolerance was due to the emigration of untolerized T cells from 
the thymus. Challenge of neonatally tolerized MRb.lpr/Ipr mice with SEB (100 #g, i.p.) at 8 
wk of age resulted in a dramatic onset of T  cell-mediated autoimmune disease characterized 
by 30% weight loss and 60% morality. This indicated that loss of tolerance to SEB also occurred 
in vivo. In contrast, neonatally tolerized MRL- + / +  mice remained totally unresponsive to SEB 
challenge and did not undergo any detectable weight loss. These results suggest  that there is 
normal induction of neonatal tolerance to SEB in lpr/Ipr  mice, but that tolerance is not maintained 
after the tolerizing antigen is removed. This loss of neonatal tolerance can lead to severe weight 
loss and death on exposure to the tolerizing antigen later in life. 
I 
n MRblpr/Ipr mice, which develop lymphadenopathy  and 
autoimmune disease, extensive studies  suggest  that ab- 
normal thymic development  results in release of increased 
numbers of T cells from the thymus before tolerance induc- 
tion, leading to excessive numbers of self-reactive T cells in 
peripheral lymphoid organs (1). This is supported by the re- 
cent finding that the Ipr gene is a mutation in the Fas an- 
tigen, which normally induces apoptosis (2--4). Although au- 
toreactive T  cells are thought to play a prominent role in 
the development of autoimmune disease, it is unclear if the 
persistence of autoreactive T cells results from a defect in in- 
duction of functional elimination either by clonal deletion 
or anergy induction, or from a defect in the maintenance of 
anergy.  The present experiments were designed  to  study 
directly defects in induction and maintenance of T cell toler- 
ance in MRL-lpr/Ipr mice. 
To better understand the mechanism of T cell tolerance 
loss in autoimmune MRL-Ipr/lpr mice, Vf18.2 TCR trans- 
genic and nontransgenic MRl..Ipr/Ipr and MRI.. + / +  mice 
were analyzed during and after neonatal tolerance induction 
by staphylococcal enterotoxin B (SEB).  1 We have previously 
shown that TCK transgenic  lpr/Ipr mice do not produce 
CD4-CD8-B220 + T cells and do not develop lymphade- 
nopathy (5). Nevertheless, these mice develop many of the 
autoimmune features typical of lff'/Ipr  mice (5, 6). Thus, anal- 
ysis of these TCK transgenic mice allows the analysis of au- 
toimmunity in Ipr/Ipr  mice that have phenotypically normal 
T  cells in  the  absence  of  the  potential  effects  of  the 
CD4-CD8-  T cell population.  In addition,  all the T cells 
1 Abbreviation used in this paper: SEB, staphylococcal enterotoxin 13. 
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therefore are potentially reactive with SEB.  Consequently, 
phenotypic and functional analyses are simplified. Finally, neo- 
natal SEB injection deletes almost all V138  + T  cells in non- 
transgenic  normal mice, making it difiicult  to analyze the 
SEB responsiveness of the few remaining V138  + T  cells (7). 
Although neonatal injection of SEB into V~/8.2 TCR trans- 
genic  mice  also  deletes  large  numbers  of V{38.2  T  cells, 
suf~cient numbers persist to allow analysis  of the compara- 
tive roles of clonal deletion and anergy induction in neonatal 
tolerance. 
Materials  and Methods 
Transgenlc Mice.  Mice expressing the single B TCR transgene 
derived from the Db/HY-specific B6.2.16 clone were constructed 
as previously described (8). 
Normal Mice.  The original breeding pairs of MtLL-Ipr/lpr  and 
MRD + / + mice were obtained from the The Jackson Laboratory 
(Bar Harbor,  ME). The TCR V138.2 transgenic mice were back- 
crossed with MRL-Ipr/lpr  and MILL-  + / +  mice, and the transgene 
was identified by probing  Southern  blots of tail DNA as previ- 
ously described (5). Transgenic mice backcrossed with MtLblpr/lpr 
mice were unambiguously  identified as Ipr/Ipr or Ipr/+ by obser- 
vation of the transgenic-negative offspring of the third backcross 
for development of lymphadenopathy and autoimmunity (5). The 
transgenic mice were backcrossed for at least 10 generations with 
MRDlpr/lpr or MILL-  + / +  mice (>99% MILL) and will be re- 
ferred to as TCIL-/3 transgenic MRDlpr/Ipr or TCR-B transgenic 
MRD +/+  mice. All mice were homozygous for H-2  k. 
Antibodies and Reagents.  Anti-CD4 (clone GK1.5), anti-CD8 
(clone 53-6.77), anti-CD3  (clone 145-2Cll), and a pan-TCR anti- 
body (clone H57-597) were purchased from PharMingen (San Diego, 
CA).  Anti-V~8 (clone KJ16.133) was obtained  from J.  Kappler 
(National Jewish Hospital, Denver, CO). Highly purified SEB was 
purchased from Toxin Technologies (Sarasota, FL). 
SEB Tolerization  and Challenge.  Neonatal tolerance to SEB was 
induced by injection of SEB intraperitoneally  (20/~g/50/~1  PBS) 
every other day from the day of birth to 2 wk of age as previously 
described (7). Challenge with SEB in vivo was carried out in SEB 
neonatally tolerized V/38 TCR transgenic  + / +  and Ipr/Ipr mice 
by injection with SEB intraperitoneally  (100 #g/200 ~1 PBS) at 
8 wk of age. 
Flow Cytometry  Analysis.  Single  cell suspensions oflymphocytes 
or thymocytes (106Aample) were stained with optimal concentra- 
tions of antibodies in PBS with 5% FCS and 0.1% sodium azide 
for 30 rain at 4~  The first-step reagent was biotin-conjugated 
anti-CD4.  Second-step reagents were a PE-conjugated anti-CD8, 
a FITC-conjugated  anti-pan-TCK,  a FITC-conjugated  anti-V~8- 
TCR (KJ16.133), or a FITC-conjugated  anti-CD3  and a Texas 
red|  tandem fluorochrome conjugated to streptavidin (Southern 
Biotechnology Associates, Birmingham, AL). Viable cells (10,000/ 
sample) were analyzed by flow cytometry on a FACScan  |  (Becton 
Dickinson  & Co., Mountain  View, CA) with logarithmic  scales. 
Purification of T Cell Subpopulations.  All cell separations were 
performed by negative selection techniques to avoid T cell activa- 
tion.  Single cell suspensions were prepared from axillary and in- 
guinal lymph nodes, spleen, and thymus.  Spleen or lymph node 
cells (10  s) were depleted of B cells and Iak-positive accessory cells 
using a magnetic  activated cell sorter  (MACS) (Miltenyi Biotec 
GmbH, Sunnyvale, CA) column.  Purified T cells were analyzed 
by flow cytometry and verified to be ;>98% CD3 +  . For some ex- 
periments,  MHC class II-positive  APC were purified from syn- 
geneic spleen cells by depletion of T cells using anti-Thy-l.2 biotin 
as the initial antibodies in the column  purification procedure. 
Stimulation by Crosslinking  of TCR or CD3.  Serial  dilutions from 
0.5 #g/ml of either anti-V~8 TCR (clone KJ16.133) or anti-CD3 
(clone 145.2Cll) mAbs were coated on flat-bottomed %-well plates 
(Costar, Cambridge, MA) by incubation for 12 h at 4~  The plates 
were thoroughly washed using sterile PBS, and purified T cells were 
added in duplicate cultures for 72 h. During the last 8 h of culture, 
1/~Ci [3H]thymidine (Amersham Corp.,  Arlington  Heights,  IL) 
was added and the amount incorporated measured using a liquid 
scintillation counter (Beckman Instruments,  Inc., Fullerton, CA). 
SEB Reactivity.  MHC class II-positive APC were obtained from 
syngeneic spleen cells that had been irradiated (3,300 tad) and T 
cell depleted by a MACS column as described above. In stimulation 
assays, T cells were purified from the lymph nodes and spleens of 
different strains of mice and incubated  with class II APC with 
varying concentrations  of SEB for 72 h. Proliferation was deter- 
mined by pulsing the wells with 1/~Ci [3H]thymidine (Amersham 
Corp.)  8 h before harvest. 
Assay oflL2 and IFN-y.  The production  of IL-2 was assayed 
by Ib2-dependent proliferation of HT-2 cells. Briefly, supernates 
were harvested from antibody-crosslinked or SEB-stimulated T cell 
cultures at 36 h and were kept frozen at  -70~  until use. 11,-2 
content was determined by [~H]thymidine (Amersham Corp.) in- 
corporation  of 5  x  103 HT-2 cells during  the last 12 h of a 24-h 
culture with the supernates. IFN-'y production  was measured by 
ELISA. Duplicate  samples were assayed in three separate experi- 
ments, and the mean was determined.  The statistical significance 
was determined using the W'rlcoxon signed-rank nonparametric test. 
Results 
Increased Reactivity to SEB in Lymph Node T Cells of SEB 
Neonatally Tolerized TCR V~8 Transgenic MRL, lpr/Ipr Mice. 
At 2 wk of age, purified T  ceils from axillary and inguinal 
lymph nodes of either SEB-tolerized V/~8 TCR transgenic 
MR.b + / +  or MRDlpr/lpr mice were unable to proliferate 
in response to SEB (Fig.  1 A), whereas purified lymph node 
T  calls from SEB-untolerized control VB8 TCR transgenic 
+ / +  and [pr/Ipr mice were able to proliferate. At 4 wk of 
age, 2 wk after SEB tolerance induction, purified T ceils from 
lymph node or spleen of V/~8 TCR transgenic MILblpr/lpr 
mice were able to proliferate in a dose-dependent fashion to 
SEB (Fig. 1 B). In contrast, purified T ceils from SEB-tolerized 
V~8 TCK transgenic MR.b + / +  mice continued to be un- 
responsive. The time course of SEB anergy loss was deter- 
mined using lymph node T  calls from SEB-tolerized TCR 
V/38 transgenic  MRD + / §  and MILL-lpr/lpr mice (Fig.  1 
C). During, and up to 1 wk after, neonatal tolerization, there 
was a significantly reduced proliferative response to SEB (10 
/~g/ml) by lymph node T cells from both Ipr/Ipr and  + / + 
mice. However, at 2 and 3 wk after SEB tolerance induction, 
there was a rapid loss of unresponsiveness leading to hyper- 
responsiveness to SEB by lymph node T cells from TCR VB8 
transgenic  MR.blpr/lpr, but not  -+/+,  mice. 
Increased IL2 and IFN-7 Production by V~8 + T Cells  from 
Neonatally Tolerized Nontransgenic and TCR V~8 ~ansgenic 
MRLlpr/lpr Mice at 4 wk of Age.  The loss of T  ceil toler- 
ance in the LN T ceils of 4-wbold neonatally tolerized Ipr/lpr 
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Figure 1.  Anergy  induction during and after neonatal tolerance induc- 
tion with SEB. The dose-response  to challenge with SEB was determined 
using (A) purified T cells from LN of tolerized and untoledzed MRD 
l~/Ipr and MRL-  + / §  2-wk-old  mice, and (B) LN or spleen of MR.b 
ltn'/Ipr and MRL-  § / + 4-wk-old  tolerized mice. The time course of the 
response to SEB challenge (10/~g/ml) was determined for purified LN 
T cells from MRL-Ipr/Ipr  and MRD + / + mice, during (2 wk) and after 
(3-5 wk) neonatal tolerization (C). Transgenic and nontransgenic MRD 
ltrr/Ipr and MR.b+/+ mice were tolerized with SEB by intrapedtoneal 
injection of 20/zg every  other day from day of  birth to 2 wk of age (toler- 
ized). 10  s T cells isolated from the LN and spleen (>98% Thy-l.2  +) were 
stimulated with SEB. The proliferative responses are expressed as cpm of 
incorporated [3H]thymidine and represent the mean _+ SEM of three ex- 
periments. 
mice was assayed by the production  of I1,2 and IFN-3' in 
response to TCR or CD3 signaling induced by different con- 
centrations  of plate-bound  anti-V38  (KJ16)  or  anti-CD3 
(145.2Cll). After TCR V38 crosslinking, there was no differ- 
ence in the production of II-2 by T cells from 4-wk-old SEB 
tolerized nontransgenic MRGIpr/Ipr mice compared to un- 
tolerized nontransgenic MR1,1pr/livr mice (Fig. 2 A). In con- 
trast, I1-2 production was markedly reduced after TCR cross- 
linking  of  T  cells  from  lymph  nodes  of  SEB  tolerized 
nontransgenic MILL- + / +  mice compared with untolerized 
nontransgenic MILL- + / +  mice. There was a linear relation- 
ship between the production of I1-2 by lymph node T  cells 
and the concentration of crosslinking antibody. The degree 
of tolerance could be quantitated by determining  the slope 
of a least-squares linear fit of I1-2 production by T cells from 
tolerized mice compared with untolerized mice (Fig.  2 B). 
This analysis indicated that at 4 wk of age, there was equiva- 
lent I1-2 production by T  cells from lymph nodes of toler- 
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ized compared to untolerized MR1,1IVr/I  F mice (slope =  1.20), 
but a 10-fold reduction in IL-2 production by T cells from 
lymph nodes of tolerized compared with untolerized MRL- 
+ /+  mice (slope  =  0.13) (iv <0.001).  Tolerance induction 
in nontransgenic MP,1, + / +  mice was specific for the sub- 
population of SEB-reactive T cells,  since T cell crosslinking 
with anti-CD3 resulted in I1,2 production in tolerized MR.L- 
+ / +  mice (Fig. 2 C). This was also indicated by the slopes 
of a least-squares linear fit of I1,2 production by lymph node 
T cells from SEB-tolerized compared with untolerized MR1, 
+ / +  (slope  =  0.79) and MRL.lpr/Zpr mice (slope  =  O.57) 
(p >0.05)  (Fig.  2 D). 
Since it was possible that  the T  cells could be anergic to 
TCR crosslinking but responsive to CD3 crosslinking,  the 
experiments were also carried out in V/~8 TCR transgenic 
mice. In V/~8 TCR transgenic MRL- 4- / 4-  mice, nearly all 
of the CD3 + T cells also express the V38 TCR.. There was 
a significant decrease in slope of the tolerized vs. untolerized 
IL-2 production curve by lymph node T cells from V38 TCR 
transgenic MILL- 4. / 4. mice compared with V/38 TCR trans- 
genic MRDlpr/Ipr mice after crosslinking  with both anti- 
V/38 (slope 4. / +  =  .37, slope Ipr =  .97, p <0.01) and anti- 
CD3 (slope § / 4-  =  0.69, slope Ipr = 2.38; iv <0.01) (Table 
1). These results indicate that neither signaling through TCR 
nor CD3 can induce equivalent I1,2 production in tolerized 
T  cells from MRD 4- / 4-  mice compared with MRL-livr/Ipr 
mice. The Ib2 response to SEB stimulation in 4-wk-old SEB- 
tolerized  mice  compared  with  untolerized  mice  was  also 
significantly reduced in T cells from nontransgenic and V38 
TCR  transgenic  MR.1, 4-/4-  mice,  compared with  MRL- 
livr/livr mice (Table 1). Supernates from all assays were also 
analyzed for IFN-% and results were in agreement to those 
found for I1,2 production  (Table  1).  These results indicate 
that loss of tolerance in T cells of livr mice includes both TCR 
and CD3  signaling,  and results in increased production  of 
both  IL-2 and IFN-q/. 
Neonatal Tolerance to SEB Is Associated with Development of 
TCR  V~8duttCD4  dutt Cells  in  Lymph  Nodes  of TCR  Vfl8 
Transgenic MRL 4- / 4-  and MRl_,lpr/Ipr Mice.  In 2-wk-old 
untolerized TCR V38 transgenic MR1, 4- / 4- mice, "~80% 
of lymph node cells expressed high levels of TCR V38 (Fig. 
3 A). These T  cells also expressed high levels of TCR ot/B 
and high levels of CD3,  and were CD4 + (57%) or CD8 + 
(23%) (Fig. 3 B). There was no significant  difference between 
2-wk-old untolerized TCR V38 transgenic MR1,1pr/Ipr mice 
and untolerized TCR V38 transgenic MRL- + / +  mice (Fig. 
3, A  and B). In contrast,  in 2-wk-old SEB-tolerized MR1, 
+ / +  mice, only 30% of lymph node T cells expressed high 
levels of TCR VB8 (Fig.  3 C). This decrease in expression 
of the Vfl8 TCR was preferential,  as 60% of peripheral  lymph 
node T  cells expressed high levels of TCR od3 and CD3. 
The  TCR  V/~8b~ig  ht  T  cells  were either  CD4 +  or  CD8 + 
(Fig.  3 D). A distinct subpopulation of TCR VB8  aun T cells 
also expressed low levels of CD4 and CD8 (Fig. 3 D). There 
was no significant  difference between 2-wk-old SEB-tolerized 
TCR V38 transgenic MLR- + / 4-  mice and 2-wk-old SEB- 
tolerized  TCR V38  transgenic MRL-Zpr/Iivr mice. 
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Figure 2.  11:2  production by LN 
T cells from SEB-tolerized nontrans- 
genic MRL-lpr/lpr  and MRL- + / + 
mice. Purified LN T cells from toler- 
ized  and  untolerized  4-wk-old 
MR1:lI~r/lpr  and MILL- + / +  mice 
were  stimulated  by  crosslink- 
ing  using  plate-bound  anti-TCR 
(KJ16.133) (A) and anti-CD3 (clone 
145.2Cll) (C) mAbs. II:2 produc- 
tion was assayed in supematants col- 
lected after 48  h.  The  activity is 
expressed  as the cpm of [3H]thy- 
midine incorporated into the HT-2 
I1:2-dependent cell  line, and rep- 
resents the mean  _+  SEM of five 
mice assayed separately in triplicate 
culture. The 11.,2 response to cross- 
linking with anti-TCR (B) and anti- 
CD3  (D)  is  compared  between 
tolerized and untolerized mice by 
least squares fit analysis. The calcu- 
lated  slope values after  anti-TCR 
crosslinking  are  1.20  for  MRL- 
1Fr/Ipr  mice (O) and 0.13 for MRL- 
+ / +  mice (&). 
of SEB Tolerization in MRI.Apr/Ipr Mice.  In 4-wk-old mice, 
2 wk after SEB tolerization had been completed, there con- 
tinued to be nearly equal numbers of V/~8 TCR  d~n and VB8 
TCR  baght T cells in V/~8 TCR transgenic MR/., + / +  mice 
(Fig.  4 and Table 2). The TCR  du" lymph node T  cells were 
predominantly  CD4d"nCDSaun  (Fig.  4  A),  whereas  the 
TCtLb~s  h~ lymph  node  T  cells  were predominantly  either 
CD4 + or CD8 + (Fig.  4 B). The TCR VB8  d"u T  cells ex- 
hibited a low forward light scatter intensity, suggesting they 
were small, resting T cells (Fig. 4C). In contrast, 2 wk after 
SEB tolerization in TCR V/~8 transgenic MR.L-Ipr/Ipr mice, 
there was a large increase of TCK VBSb'ig  ht T  cells in the 
lymph node (Fig.  4).  These T  cells were either  CD4 + or 
CD8 + (Fig.  4 B), and most exhibited a high forward light 
scatter, suggesting that these cells were activated. There was 
also a small population of TCR  au" lymph node T  cells that 
exhibited low forward light  scatter  consistent  with  small 
resting  T  cells  (Fig.  4  C). 
Reduction of Total Lymphocyte  Population during and after SEB 
Tolerization.  Compared with untreated  mice,  there was a 
Table  1.  Production  Ratio of IL-2 and IFN-~/ in 4-wk-old SEB-tolerized Compared with Untolerized Mice 
Anti-V38  (KJ16)  Anti-CD3  SEB 
v38 TCP, 
Strain  transgenic  IL-2  IFN-y  IL-2  IFN-~/  IL-2  IFN-',/ 
MRL-Ipr/Ipr 
MILL-+/+ 
MPJApr/tpr  + 
MILL-+/+  + 
1.20"  4.44*  0.79  1.02  1.19"  ND 
(r  =  0.92)  (r  =  0.90)  (r  =  0.97)  (r  =  0.99)  (r  =  0.89) 
0.13  0.26  0.57  0.71  0.33  ND 
(r  =  0.89)  (r  =  0.92)  (r  =  0.97)  (r  =  0.48)  (r  =  0.74) 
0.97*  0.39*  2.38*  0.61"  0.93*  0.62* 
(r  =  0.75)  (r  =  0.86)  (r  =  0.92)  (r  =  0.77)  (r  =  0.93)  (r  =  0,90) 
0.37  0.037  0.69  0.25  0.11  0.25 
(r  =  0.78)  (r  =  0.89)  (r  =  0.99)  (r  =  0.87)  (r  =  0.86)  (r  =  0.83) 
T  cells isolated from the LN of SEB-tolerized or untolerized mice were stimulated by plate-bound anti-TCR (KJ16) or anti-CD3 as in Fig. 2, or 
SEB as in Fig.  1. The production of IL-2 and IFN-'y was assayed,  and a least squares  linear fit of the results from tolerized and untolerized mice 
carried out,  as described in Fig. 2.  The ratio of the production rate in the tolerized compared with the untolerized mice is presented with the r 
value in parenthesis. A slope value of 1 indicates that the responses from tolerized mice have a dose-response similar to untolerized mice (i.e., failure 
to induce or maintain tolerance). 
" Value in MRL-lpr/Ipr mice is significantly different from MILL- + / +  mice. 
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Figure 3.  Expression  of TCR V/~8, 
TCK-c~//3,  CD3,  CD4,  and  CD8 
during induction of neonatal tolerance 
to SEB in transgenic  mice. LN cells 
from untolerized 2-wk-old transgenic 
mice were stained with anti-V/~8  TCR 
(KJ16.133), anti-pan-TCR  ot//~ and 
anti-CD3 (clone 145.2Cll) (A), and 
compared  with  mice  undergoing 
tolerization (C) by FACS  |  analysis. 
Horizontal axes illustrate  the log of 
fluorescence, and vertical axes illustrate 
relative cell numbers. Cells were also 
triple stained with biotin-conjugated 
anti-CD4, then PE-conjugated  anti- 
CD8,  FITC-conjugated  anti-VB8 
TCR,  and  a Texas red|  tandem 
fluorochrome  conjugated  to  strep- 
tavidin.  The coexpression  of TCR 
VB8 and CD4 and CD8 is shown for 
untolerized (/3) and tolerized (19) mice. 
The fluorescence histograms and con- 
tour plots  are representative  of four 
different experiments, and the percent 
of cells in each quadrant  is noted in 
the figure. 
three- to fourfold reduction of  total lymphocytes  in SEB-treated 
V/~8 TCR transgenic MRIr + / +  and MRL-lpr/Ipr  mice at 
2 wk of age (Table 2). At 3 wk of age, I wk after stopping 
SEB, the total number of lymph node cells in TCR. trans- 
genic V/38 transgenic  MRI.-Ipr/Ipr mice had returned to 
normal, whereas the number of lymph node cells in TCR 
Table  2.  Total  Number  of Lymph  Node  Cells  in  Untolerized  and  SEB-tolerized  Mice 
2  wk old  3  wk  old  4  wk old 
V/38  TCIL  SEB  V~8 bright  V~8  bright  V•8  bright 
Strain  transgenic  tolerized  Total  total  Percent  Total  total  Percent  Total  total  Percent 
MILL-Ipr/lpr  +  +  2.8  +  .6  1.1  38  28.3  _+  2.1  13.9  49  32.8  _+  5.1  19.0  58 
MRL-+/+  +  +  2.2  _+  .8  0.70  32  7.1  _+  0.8  0.64  9  17.3  _+  3.5  3.6  21 
MRL-Ipr/Ipr  -  +  9.9  +  1.2  0.0  0  28.3  _+  1.7  1.7  6  31.2  +  2.9  3.7  12 
MRL-+/+  -  +  6.5  _+  .8  0.0  0  28.1  _+  1.9  0.0  0  29.2  _+  2.2  0.29  1 
MRL-lpr/Ipr  +  -  8.9  +  1.2  5.7  64  31.5  _+  2.6  23.9  76  32.2  _+  4.1  21.6  67 
MR.L-+/+  +  -  8.6  +  1.1  6.5  75  13.7  _+  1.2  11.1  81  20.4  _+  3.9  14.7  72 
MRL-Ipr/Ipr  -  -  8.3  +  .9  1.2  14  27.5  _+  2.1  4.7  17  44.5  _+  3.8  6.7  15 
MR.L-+/+  -  -  11.2  +  1.3  2.1  19  13.2  _+  1.1  2.2  17  18.3  _+  1.2  2.9  16 
FACS  ~ analysis was used to determine the percentages of V/38b~s  h' cells, as in Figs. 3 and 4. Values for total LN cells are presented as the mean  _+  SEM 
( x 10 -6)  of three experiments  with five mice per group￿9 
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Figure 4.  Expression of TCR VB8, CD4, and CD8 in relation to LN 
T cell size in neonatally tolerized transgenic mice. LN region cells from 
4-wk-old mice, 2 wk after stopping SEB treatment, were stained as de- 
scribed in Fig. 3 and FACS  |  gated into TCK VB8 (top)  dull (region A) 
and TCR VB8 bright (region B) populations, and analyzed for expression 
of CD4 and CDg. A contour plot of cell size (estimated by light scatter) 
vs. the expression of TCR VB8 is shown in C. In this plot, the regions 
of dull, intermediate,  and bright expression of TCR VB8 are the same 
as defined in the TCR V~8 histograms. The histograms and contour plots 
are representative of four different experiments with five mice per group. 
V/~8 transgenic MRL- + / +  mice were reduced compared with 
untolerized control mice. At 4 wk of age, the number of 
lymph node T cells in tolerized MRL- + / +  mice was equiva- 
lent to untolerized control mice. A more accurate indication 
of the effects of SEB tolerization on the lymph node T cells 
was  obtained  by  comparison  of  the  number  of  V~/8 
TCRb~s  ht T cells. The value was obtained by multiplying the 
total number of lymph node cells by the percent of V/38 
TCRb'ig  ht T cells determined by flow cytometry analysis. At 
2 wk of age, there was five- to sixfold reduction of VB8 
TCRb'~g  h~  T  cells in  SEB-tolerized  V/~8 TCR  transgenic 
MILL- + / +  and MtLL-Ipr/lpr mice compared with untoler- 
ized control mice. At 3 wk of age, there was no increase in 
VB8 TCRb'ig  ht T cells in SEB-tolerized V/38 TCR transgenic 
MRL- + / +  mice, but there was a return of V/38  b'igh' T cells 
in VB8 TCR transgenic MRL-Ipr/Ipr mice to 60% of that 
found in untolerized controls.  At 4 wk of age, there was a 
partial recovery of the number of V/~8  b'igh~ T cells in toler- 
ized VB8 TCR transgenic MRL-+//+  mice. A similar pat- 
tern of recovery of VB8b'ig  ht T  cells was observed in non- 
transgenic SEB tolerized MRL-Ipr/Ipr compared to MRL- +/+ 
mice (Table 2). 
Effect of SEB Tolerization on Thymocytes.  The thymus of 
VB8 TCR transgenic mice undergoing SEB tolerance induc- 
tion was analyzed by flow cytometry  to determine if a defect 
in clonal deletion of VB8 + T cells exists in Ipr mice. There 
was effident depletion of VB8  bright T cells in the thymus of 
both VB8 TCR transgenic MILL-  +/+  and Ipr/Ipr mice  just 
after SEB tolerance induction at 2 wk of age (Fig. 5). This 
resulted in a near total loss of mature CD4  br~ht and CD8  bright 
thymocytes. In contrast to the phenotypic difference  of  lymph 
node T cells from 4-wk-old SEB-tolerized TCR VB8 trans- 
genic MRL- + / +  mice compared with MRDlpr/Ipr mice, 
there was no difference in the phenotype of thymocytes in 
4-wk-old TCR transgenic  MILL-+/+  mice compared  to 
TCR transgenic MRL-Ipr/Ipr mice (Fig. 5 C). However, there 
was a more rapid recovery of total thymocytes in 4-wk-old 
SEB-tolerized TCR V~8 transgenic MRL.Ipr/Ipr (110 _+ 4.5 
X  10  6) compared with TCR VB8 transgenic  MRIr +/+ 
(67.5  -!-_  7  x  106) mice. 
Increased SEB Reactivity of Thyraocytes from  Ipr/Ipr Mice. 
Neonatal tolerance induction with SEB reduced thymocyte 
proliferation in response to SEB and KJ16 crosslinking at 2 wk 
of age in both TCR VB8 transgenic MRD + / +  and M1LL- 
Ipr/Ipr mice (Fig. 5, D and E). Despite the similar pheno- 
type, there was a rapid increase in SEB- and KJ16-stimulated 
responsiveness of thymocytes from TCR VB8  transgenic 
Ipr/Ipr, but not TCR VB8 transgenic  + / +, mice at 3, 4, 
and 5 wk of age. The proliferative response of thymocytes 
to SEB or KJ16 crosslinking at 4 and 5 wk of age from TCR 
V~8 transgenic MRL.Ipr/Ipr  was greater than the response 
in untolerized 4-5-wbold mice, indicating SEB induces hyper- 
responsiveness to thymocytes from MRI.-Ipr/Ipr mice. 
Loss of Neonatal Tolerance in MRL.Ipr/lpr Mice Originates 
in the Thymus.  Loss  of SEB-induced  neonatal tolerance occurs 
between 1 and 2 wk after neonatal  tolerance induction in 
both the thymus and lymph node. Peripheral tolerance loss 
could be due to either production of new untolerized thymo- 
cytes or due to spontaneous loss of anergy by lymph node 
T cells, or a combined loss of anergy in the thymus and lymph 
node. To distinguish among these possibilities, SEB neonatal 
tolerized V/~8 TCR transgenic MILL-  + / +  and MRL-lpr/lpr 
mice were either thymectomized  or sham thymectomized  at 
2 wk of age, just after induction of tolerance. The reactivity 
of lymph node T  cells to SEB was then analyzed at 4 wk 
of age. As expected, lymph node T cells from SEB-tolerized 
sham-thymectomized, VB8 TCK transgenic MR3:Ipr/Ipr mice 
were highly responsive to SEB, whereas SEB tolerized sham- 
thymectomized MILL-  + / +  mice remained tolerant (Fig. 6 
A). In contrast,  lymph node T  cells from thymectomized, 
SEB-tolerized V/~8 TCR transgenic MRL, lpr/Ipr mice re- 
mained tolerant to SEB. This can also be seen by plotting 
the ratio of the proliferative response of lymph node T cells 
from SEB-tolerized MRL-Ipr/Ipr mice compared with SEB- 
tolerized MILL-  + / + mice for different concentrations of SEB 
(Fig. 6 B). Lymph node T cells from sham-thymectomized 
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Fib~tre 5.  Analysis  of thymocytes 
from V~8 transgenic mice during 
and after SEB tolerization. Thymo- 
cytes from 2-wk-old  untolerized (.4) 
and SEB-tolerized (B) mice, and 
4-wk-old SEB-tolerized mice (C), 
were analyzed  for the expression  of 
TCK V/~8, CD4, and CD8 as in 
Fig. 3. The total number of thymo- 
cytes (mean  +  SEM) are shown 
above the panels. The time course 
of  the  proliferative response of 
thymocytes  to stimulation with SEB 
(10 #g/ml) (/9) and to crosslinking 
by plate-bound KJ16  mAbs (E) was 
estimated by [3H]tbymidine  incor- 
poration as in Figs. 1 and 2. Results 
were derived  from three experiments 
with five mice per group. 
VB8 TCK transgenic MRL-Ipr/Ipr mice exhibited a 15 times 
greater proliferative response compared with  T  cells  from 
equivalently treated VB8 TCK transgenic MRL + / +  mice 
(slope  =  15.3).  In contrast,  there was no difference in re- 
sponsiveness comparing thymectomized MR~Ipr/Ipr to MRI: 
+/+  mice (slope =  1.03). These results indicate that failure 
to maintain peripheral T cell tolerance in MRI~Ipr/Ipr mice 
is due to an export of new untolerized T cells from the thymus 
to the periphery. 
Loss of Tolerance In  Viva  To  determine  if the  loss  of 
neonatal-induced tolerance to SEB occurs in vivo as well as 
in vitro, SEB neonataUy tolerized VB8 TCK transgenic  + / + 
and Ipr/Ipr mice were injected with SEB (100/~g, i.p.) at 8 
wk of age. There was a marked weight loss and a 60% mor- 
tality in Ipr/lpr mice, but no effect in  + / +  mice (Fig.  7). 
In contrast, untolerized V38 TCK transgenic  + / +  and lpr/Ipr 
mice had equivalent weight loss and no mortality after injec- 
tion with SEB (100 #g, i.p.) at 8 wk of age, comparable to 
previously reported SEB-induced weight loss (9,  10). 
Discussion 
T cell tolerance induction after SEB administration has pre- 
viously been shown to involve both anergy induction  and 
clonal deletion (11, 12).  The effects of T  cell activation by 
SEB are seen within i wk of SEB administration and consist 
of a limited expansion followed by clonal deletion of 50% 
of T cells (11). The remaining V~8 + T cells do not respond 
to SEB. Biweekly administration  of SEB into MRL-Ipr/Ipr 
mice also resulted in decreased CD4-CDS-B220 + T  cells 
and renal disease (13). The present experiments indicate that 
induction  of T  cell anergy and clonal deletion does occur 
in autoimmunme  lpr/Ipr mice, but is slightly less efficient 
than that observed in  + / +  mice. This result is consistent 
with previous reports that in the presence of the self-antigen, 
clonal deletion of self-reactive (Mls, MHC) T cells does occur 
in Ipr/Ipr  mice (14-16). We also previously demonstrated that 
in  Db/HY  TCK  transgenic  C57BL/6-1pr/l_pr male  mice, 
there was a small but detectable difference in intrathymic clonal 
deletion of self-reactive T  cells  (6). 
Anergy induction with SEB is associated with the devel- 
opment of TCRdunCD4a~CD8 auu T cells in lymph node of 
V/~8 TCK transgenic MR.L + / +  and MRL-lpr/Ipr mice. Cell 
size analysis indicates these are small, resting T cells. In TCR 
V~8 transgenic mice, downregulation of V~8 may occur in 
a unique manner. There is normal expression of TCKo~/~ and 
CD3 despite low levels of VBS, suggesting that there is simul- 
taneous  expression  of endogenously rearranged  TCK  V~ 
regions, as well as the TCK V~8 transgene (Fig. 3 C). The 
transgenic VB8 gene has been found to efficiently suppress 
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Figure 7.  SEB-induced  weight  loss (.4) and survival (B) in SEB neona- 
tally tolerized  V~8 TCK transgenic MRDlpr/lpr  and MR.U  + / + mice. 
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mice were challenged  with SEB in vivo (100 #g, i.p.) at 8 wk of age. 
The mean (+_  SEM) values of five mice are presented. 
endogenous V/~ rearrangement (8). SEB tolerization results 
in extensive  donal deletion of thymocytes exhibiting high 
expression  of VB8 TCR resulting in increased visibility of 
the few thymocytes that express low levels of endogenously 
rearranged TCR V/~ regions and low expression of the V~8 
transgene. Other investigators have previously observed the 
development CD4- CD8 - CD5 +  IL-2R  + T cells in nontrans- 
genic mice after treatment with SEB (17). In addition, we 
have previously observed downregulation of CD8 on T cells 
from the spleen of Db/HY-reactive  TCR transgenic D b male 
+ / +  and Ipr mice (6). SEB-induced TCRa~mCD4a~CD8 a~ 
T cells are seen during anergy induction in both transgenic 
and nontransgenic (data not shown) MILL-  + / +  and MILL- 
lpr/tpr mice. Therefore, this T cell phenotype is a feature of 
neonatal anergy induction in normal mice, and is not related 
to the Ipr gene or TCR transgene. 
Although there is a small tolerance defect in Ipr/Ipr mice 
during anergy induction with SEB, the main defect occurs 
within 1 wk after stopping SEB, suggesting different mech- 
anisms underlie induction and maintenance of tolerance. The 
Ipr defect has been found to be due to a mutation of the Fas 
antigen, which mediates apoptosis in the thymus (2-4). The 
observation of nearly normal intrathymic clonal deletion in- 
dicates  that negative selection can occur in the thymus of 
lpr/Ipr mice despite the mutated Fas antigen. The rapid re- 
turn of SEB-reactive thymocytes after stopping SEB suggests 
that a Fas-dependent thymic apoptosis pathway is required 
for maintenance of T  cell tolerance to SEB. Tolerance  loss 
in the thymus of Ipr/lpr mice is not simply due to increased 
production of thymocytes, because by 4 wk of age, there is 
a two- and threefold increase in thymocytes in  +/+  and 
Ipr/Ipr mice, respectively, but there is a much greater increase 
in thymocyte proliferation after stimulation with SEB and 
KJ16 crosslinking by thymocytes  from Ipr/tpr compared with 
+ / +  mice (Fig. 5). One possibility is that the Fas-dependent 
pathway is primarily used to eliminate "neglected" thymo- 
cytes. During SEB tolerization, SEB-reactive TCR VB8 + T 
cells would be highly reactive  due to bridging of the Vfl8 
TCP, and thymic MHC antigens by the SEB superantigen. 
Consequently, there would be few neglected VB8 + T cells, 
and  extensive donal  deletion of most  VB8 +  thymocytes 
would occur.  However, after SEB tolerization is  stopped, 
neglected TCR VB8 + T  cells would be produced in high 
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mice. In MRL- + / +  mice, we propose that neglected VB8 + 
T cells would undergo apoptosis primarily due to signaling 
through the Fas antigen. However, in MtLblpr/Ipr mice, such 
neglected thymocytes would not undergo apoptosis due to 
the Fas defect, nor would they undergo negative selection, 
as they would be neglected by the thymus. These VB8 + T 
cells would persist in the thymus and escape to the periphery 
and remain reactive with SEB. The importance of new thymo- 
cytes in tolerance loss is demonstrated  by the observation that 
MILL-lpr/lpr mice do not have a significant defect in main- 
tenance of peripheral tolerance in the absence of the thymus, 
as thymectomy of SEB-tolerized mice at 2 wk of age com- 
pletely eliminated the loss of tolerance to SEB at 4 wk of age. 
The proposal  that  Fas mediates  apoptosis  of neglected 
thymocytes is consistent with our previous observation that 
a rearranged TCR gene inhibits lymphoproliferative disease 
by inhibiting production of CD4 +  CD8 +  TCR  ~  T cells (5). 
In nontransgenic mice expressing endogenously rearranged 
TCK genes, a large percentage  of CD4 +  CD8 +  TCR  a~ T 
cells are thymocytes  that fail to properly rearrange or express 
the TCK, resulting in production of neglected thymocytes 
that undergo apoptosis in the thymus (18). In lpr mice, the 
Fas defect in the apoptosis of neglected thymocytes might 
lead to escape of increased numbers of these unselected T cells 
to the periphery, resulting in lymphadenopathy and autoim- 
munity.  We  propose  that  a  rearranged  TCK  transgene 
eliminates lymphoproliferation by decreasing production of 
neglected cells due to abnormal TCK rearrangement. 
We cannot yet fully explain how a TCK transgene might 
inhibit a defective Fas-dependent pathway of thymocyte de- 
velopment, yet not eliminate autoimmune features of Ipr mice 
(5, 6). Failure to eliminate autoantibody production could 
be due to the requirement that B cell development in Ipr/Ipr 
mice is  also affected by the defected Fas-related apoptosis 
pathway, resulting in autoreactive B cells. This is consistent 
with the observation  of an intrinsic B cell defect in Ipr/lpr 
mice (19). A B cell abnormality,  by itself, has been noted 
to result in autoantibodies,  but not severe autoimmune dis- 
ease (20). In addition to B cell abnormalities, we find an in- 
crease in autoreactive T cells expressing the rearranged TCK 
transgene in the TCK transgenic lpr/Ipr mice (6). It is pos- 
sible that the Fas antigen plays a role in negative selection 
and donal deletion of autoreactive T  cells, as well as on 
neglected T cells. Alternatively, as described above, some of 
the T cells expressing the self-reactive  TCK transgene might 
develop into neglected thymocytes requiring Fas-induced  apop- 
tosis. In both cases, TCK transgenic  mice would produce 
abnormal,  potentially  autoreactive  T  cells, but  at  lower 
numbers compared with nontransgenic mice. This is sup- 
ported by the data in Table 1, in which the production ratio 
for II.-2 and IFN-3, in tolerized relative to untolerized mice 
is reduced in the presence of the TCK V~8 transgene. A third 
possibility is that some aspects of organ disease in lpr mice 
might be related to failed apoptosis of abnormal cells unrelated 
to immune defects. Fas is expressed in the heart, liver, and 
ovaries (4), and defective apoptosis of cells at nonlymphoid 
sites might lead to tissue damage associated  with mononuclear 
cell infiltrate. This is exemplified by the observation that sy- 
novial  hyper-proliferation  in  MRL.Ipr/lpr  mice  has  been 
reported to precede T cell infiltration  and might be related 
to an apoptosis defect of a synovial cell (21). 
SEB has previously been shown to induce rapid weight 
loss after in vivo administration in normal mice, which was 
initially proposed to be due to production of Ib2 (9). The 
data presented in this paper indicate that after neonatal toler- 
ance induction, SEB does not induce weight loss in TCR 
V~8 transgenic MILL-  + / +  mice, but induces a greater than 
normal weight loss and 60%  mortality in SEB neonatally 
tolerized TCK V~8 transgenic MILL-Ipr/Ipr  mice. This SEB 
hyper-responsiveness in vivo is consistent with the in vitro 
tolerance studies in which after 5 wk of age, a greater than 
normal response of T cells from neonatally tolerized MRL- 
lpr/Ipr mice to SEB was observed compared with untolerized 
mice. SEB has also been shown to induce TNF-ol, Ibl, and 
Ib6  production by blood mononuclear cells (22). These 
cytokines have been found to be increased in lpr/Ipr mice (23, 
24), and release of cytokines in vivo could lead to an acute 
septic shock-like state, weight loss, and death. 
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